Ocular Therapeutix
OCULOCUL · Stock Price
Historical price data
Overview
Ocular Therapeutix's mission is to redefine the treatment of ophthalmic diseases by leveraging its proprietary hydrogel technology to create sustained-release therapies that reduce the high frequency of interventions required by current standards of care. The company has successfully transitioned to commercial operations with DEXTENZA® and is now on the cusp of a major value inflection with its lead candidate, AXPAXLI™ (axitinib implant), under FDA review for wet AMD. Its strategy centers on addressing the critical unmet need of treatment burden to improve patient adherence and visual outcomes, thereby capturing significant share in multi-billion dollar retinal markets.
Technology Platform
A proprietary, bioresorbable hydrogel platform based on polyethylene glycol (PEG) and polyethylene oxide (PEO) designed for sustained drug delivery in the eye, with tunable release kinetics and full biodegradation.
Pipeline
52| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Dextenza + Prednisolone Acetate | Keratoconus, Unstable | Approved | |
| Dexamethasone Intracanalicular Insert, 0.4mg with LipiFlow T... | Dry Eye Syndromes | Approved | |
| Dextenza 0.4Mg Ophthalmic Insert + Prednisolone Acetate | Neovascular Age-related Macular Degeneration | Approved | |
| Dexamethasone ophthalmic insert 0.4Mg + 0.2% loteprednol eta... | Bilateral Conjunctivitis (Disorder) | Approved | |
| Omidria + Dextenza (dexamethasone ophthalmic insert) 0.4mg +... | Cataract Surgery | Approved |
FDA Approved Drugs
1Opportunities
Risk Factors
Competitive Landscape
In wet AMD, AXPAXLI competes on superior durability (6-9 months) versus standard anti-VEGF injections and high-dose aflibercept, and a more favorable profile versus permanent implants like Susvimo. In dry eye and glaucoma, its sustained-release implants compete against daily drop regimens, offering a novel compliance solution rather than a new molecule.
